Brolucizumab

Specification

• Cat#: THA-0118
• Product Name: Brolucizumab
• Description: Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
• Sequences: Not Available
• Molecular Weight: 26000.0 Da (approximate)
• Introduction: Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration. Brolucizumab was granted FDA approval in October 2019.
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Appearance: Solid
• Endotoxin Level: < 0.001 EU/μg of the protein by the LAL method

Pharmaceutical Information

• Pharmacodynamics: Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. It has a long duration of action as it is given monthly. Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication.
• Targets: Vascular endothelial growth factor A, long form